Randomized placebo‐controlled trial of losartan for pediatric NAFLD

• Published in: Hepatology (Baltimore, Md.) Vol. 76; no. 2; pp. 429 - 444
• Main Authors: Vos, Miriam B., Van Natta, Mark L., Blondet, Niviann M., Dasarathy, Srinivasan, Fishbein, Mark, Hertel, Paula, Jain, Ajay K., Karpen, Saul J., Lavine, Joel E., Mohammad, Saeed, Miriel, Laura A., Molleston, Jean P., Mouzaki, Marialena, Sanyal, Arun, Sharkey, Emily P., Schwimmer, Jeffrey B., Tonascia, James, Wilson, Laura A., Xanthakos, Stavra A.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.08.2022
• Subjects: Adolescent; Alanine; Alanine transaminase; Alkaline phosphatase; Angiotensin; Angiotensin II; Angiotensin Receptor Antagonists - therapeutic use; Blood Pressure; Child; Children; Clinical trials; Coronaviruses; Double-Blind Method; Drug therapy; Female; Hepatology; Humans; Hypertension - drug therapy; Losartan - adverse effects; Losartan - therapeutic use; Male; Non-alcoholic Fatty Liver Disease - chemically induced; Non-alcoholic Fatty Liver Disease - drug therapy; Pediatrics; Placebos; Treatment Outcome

Background and Aims To date, no pharmacotherapy exists for pediatric NAFLD. Losartan, an angiotensin II receptor blocker, has been proposed as a treatment due to its antifibrotic effects. Approach and Results The Nonalcoholic Steatohepatitis Clinical Research Network conducted a multicenter, double‐...